Baird Lowers its Price Target on Nyxoah SA (NYXH) to $4.62 from $5.87

Nyxoah SA (NASDAQ:NYXH) is 1 of the

7 Fastest Growing European Stocks to Invest In. On March 23, 2026, Baird expert David Rescott lowered the terms people connected Nyxoah SA (NASDAQ:NYXH) to $4.62 from $5.87 and maintained a Neutral rating, citing exemplary updates arsenic the company’s U.S. rollout begins to summation traction but remains successful its aboriginal stages.

On March 20, 2026, Stifel lowered its terms people connected Nyxoah SA (NASDAQ:NYXH) to $10 from $11 antecedently and maintained a Buy rating, noting exemplary adjustments tied to respective moving parts.

On March 19, 2026, Nyxoah SA (NASDAQ:NYXH) reported Q4 EPS of (EUR 0.59), compared to (EUR 0.46) a twelvemonth ago, with gross of EUR 5.64M versus EUR 1.26M past year. Chief Executive Officer Olivier Taelman said the 4th marked the company’s archetypal afloat play of U.S. commercialization, with gross exceeding expectations and affirmative feedback from surgeons and patients, alongside accordant reimbursement from large payors and Medicare.

Copyright: kadmy / 123RF Stock Photo

The institution expects U.S. nett gross to turn astir 25% sequentially successful some Q1 and Q2 of 2026, portion planetary gross is expected to travel emblematic seasonal patterns.

Nyxoah SA (NASDAQ:NYXH) develops neurostimulation therapies to dainty obstructive slumber apnea.

While we admit the imaginable of NYXH arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 33 Stocks That Should Double successful 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. 

Disclosure: None. Follow Insider Monkey connected Google News.